Research casts doubt on combo cancer therapies; Sierra Oncology drug improves anemia and other myelofibrosis symptoms

A growing body of evidence is beginning to shatter the idea that "synergy" in drug combinations should be a high priority in cancer research.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Biomarkers are changing the way that doctors treat cancer. At a Feb. 2 event, STAT takes a look at some of the latest technological advances. Register now. STAT+: New research casts doubt on how combination cancer therapies work in tandem By Angus Chen AP/Business Wire A growing body of evidence is beginning to shatter the idea that “synergy” in drug combinations should be a high priority in cancer research. Read More STAT+: Pivotal study shows Sierra Oncology drug improves anemia and other symptoms of myelofibrosis By Adam Feuerstein Adobe Based on the positive study results, Sierra intends to file a U.S marketing application for its drug during the second quarter. Read More STAT+: Once billed as a revolution in medicine, IBM's Watson Health is sold off in parts By Casey Ross Hyacinth Empinado/STAT; Eros Dervishi for STAT IBM will sell core assets of Watson Health to a private equity firm, marking the collapse of its ambitious artificial intelligence effort. Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit At this March 31 event, executives, researchers, scientists, and investors will take the stage to discuss the technologies and procedures at the cutting edge of health and medicine. Get your ticket now to learn about the latest efforts to battle diseases and help patients. They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases By Matthew Herper Adobe The U.K. non-profit Protas received $6.8 million to begin its work to accelerate how clinical trials are done and make them far cheaper. Read More Opinion: It's all in the details: start-up packages and ongoing gender bias in academic medicine By Jennifer Rubin Grandis Adobe In academic medicine, the resources in one's start-up package can help explain how gender bias cumulatively disadvantages women in the field. Read More Tuesday, January 25, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser